Actively Recruiting
Social and Psychological Long-term Impact of NMDA Receptor Encephalitis, Level 3
Led by Hospices Civils de Lyon · Updated on 2026-02-17
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
H
Hospices Civils de Lyon
Lead Sponsor
C
Charite University, Berlin, Germany
Collaborating Sponsor
AI-Summary
What this Trial Is About
NMDA receptor antibody encephalitis is a rare autoimmune neurological condition affecting the central nervous system, causing symptoms like psychosis, memory loss, seizures, and coma during its acute phase. While the acute phase has been well studied since its discovery, the long-term social and psychological impacts on patients, especially young adults around a median age of 21, are not well understood. This research aims to evaluate how this disease affects patients' cognitive function and daily social and professional life after the acute phase. Participants in this observational study are adults diagnosed with NMDAR encephalitis who have completed the acute phase of the disease. The study involves completing several quality of life questionnaires that assess fatigue, anxiety, depression, sleep quality, and overall health status. These assessments are done at the time of inclusion to understand the lasting effects of the disease on patients' well-being. During the study, patients will complete various cognitive and psychosocial questionnaires such as PREMS, AEPREM, FSS, GAD7, PHQ9, PSQI, and EQ-5D-5L. The researchers will analyze these responses to measure cognitive impairments and psychosocial challenges after the acute illness. The study is observational and does not involve any treatment interventions. Participants can expect to provide information through online questionnaires using a computer and internet connection. The study duration and follow-up details are not specified.
CONDITIONS
Brief Title
Long-term Impact of NMDAR Encephalitis, Level 3
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with NMDAR encephalitis
- Age 65 18 years old
- Patient affiliated to a social security system
- No opposition from the patient
- Access to an internet connection and a computer
You will not qualify if you...
- Patients without NMDAR encephalitis
- Patient under guardianship or curatorship
- Patient with neurological disorders pre-existing encephalitis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - At inclusion
Participants complete quality of life questionnaires focusing on fatigue, anxiety, depression, and sleep to assess their cognitive and psychosocial status after the acute phase of NMDAR encephalitis.
1 visit (remote or in-person) to complete questionnaires
Duration - Up to the study completion date in November 2026
Participants are observed over time to assess the social and psychological long-term impact of NMDAR encephalitis.
Follow-up assessments may occur depending on participant availability
Trial Site Locations
Total: 1 location
1
Centre de référence des syndromes neurologies paranéoplasiques et encéphalites auto-immunes - Hôpital neurologiques Pierre WERTHEIMER - Groupement hospitalier Est - Hospices civiles de Lyon
Bron, France, 69500
Actively Recruiting
Research Team
J
Jérôme HONNORAT, Pr
C
Chloé BUTTARD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here